Abiomed (ABMD) 8-K Results of Operations and Financial Condition

May 18, 2009 Conference Call

Michael Minogue, Chairman, President and CEO

Robert Bowen, CFO

(NASDAQ: ABMD)

May 8, 2009

Exhibit 99.2

2

Legal Disclaimers

Not FDA

Approved, See Disclaimer

Red Box Indicates

This information includes forward looking statements including statements regarding the future

financial performance, product development efforts, ABIOMED’s strategic operational initiatives,

and market response to ABIOMED’s new products. ABIOMED’s actual results may differ materially

from those anticipated in these forward-looking statements based upon a number of factors,

including uncertainties associated with the development, testing

and related regulatory approvals,

competition, technological change, future capital needs, and other risks detailed in the Company’s

filings with the Securities and Exchange Commission. You are cautioned not to place undue

reliance on any forward-looking statements, which speak only as of today’s date. The Company

undertakes no obligation to publicly release the results of any revisions to these forward-looking

statements that may be made to reflect events or circumstances that occur after today’s date or to

reflect the occurrence of unanticipated events.

IMPELLA®

Pediatric, Implantable, Right Percutaneous are Not Available for Sale in the United States.

AbioCor®

II is not approved by the FDA for Sale in the United States

3

Impella 2.5

510(k) Clearance 6/08

CE

Impella Console

CE

Impella

Pediatric

Impella Right

Percutaneous

Intra-aortic Balloon

510(k), CE

BVS Blood Pump

FDA Approved, CE

New Products & Regulatory Execution

AB5000 Ventricle

FDA Approved, CE

Not FDA

Approved, See Disclaimer

Impella

Cath Lab/ Percutaneous Placement

PMA

Supplement

4/09, CE

iPulse

FDA Approved,

CE

iPulse

Surgical VAD Placement

Impella 5.0 / LD

510(k) Clearance  4/09

CE

1/14/09

Impella 510(k) US Launch FY09 = 521 Patients

Q2*: June to Sept. 2008

•

100 patients in 4

months, 6 a week avg.

•

$6.2M US Q2

commercial revenue

•

@ 108 Hospitals

•

35% reorder revenue

Q3: Oct to Dec. 2008

•

160 patients, up 60%, 

13 a week avg.

•

$6.7M US Q3, up 8%

sequentially

•

Added 55 accounts @

163 Hospitals, up 51%

•

48% reorder revenue

4

(*US News & World Reports)

Q4: Jan to March 2009

•

261 patients, up 63%,  22

a week avg.

•

$9.1M US Q4, up 37%

sequentially

•

Added 66 accounts @

229 Hospitals, up 40%

•

>50% reorder revenue

Total  Worldwide Impella revenue

$10.6M

Total  Worldwide Impella revenue

$8.8M

Total  Worldwide Impella revenue

$11.2M

5

5

Why we believe Impella

is Superior to IABP

Direct

Heart

Unloading…reducing

O

2

demand

on

heart

Supporting

Coronary

Flow…increasing

O

2

supply

to

heart

Increasing

Cardiac

Power…increasing

O

2

supply

to

all

organs,

the

highest

correlate

to

decreasing

mortality

Impella

IABP

5

6

Impella Technology …

Validated in Studies

7

Showcasing Impella

Superiority Over IABP

MACH II

Impella

Improves Ejection Fraction in AMI

3 Days        

% Pts. Improvement in Ejection Fraction (EF)

2%

5%

9%

13%

120 Days        

Impella

2.5        

Standard of Care

p<0.05

ISAR-SHOCK

Impella

Provides 5X Better Hemodynamic Support Than IABP

in AMI Cardiogenic

Shock

(Seyfarth

et al. American College of Cardiology, 2007)

P<0.01

1.10

0.20

0.25

1.25

0.75

0.50

1.50

0

Impella

IABP

PAMI-II:

No Benefit in Mortality or LV Function for IABP

(n=211)

(Stone et al, J ACC29:1459, 1997)

Cardiac Power Output

(n= 20)

(n= 26)

(Fincke

R

et

al.

JACC

2004

Vol

44,

n2:

304-8)

(Henriques

et al. American College of Cardiology, 2007)

Strongest Hemodynamic Correlate of Mortality

Cardiac Power Output

(n=189)